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The levels of nitric oxide and metabolites in Behçet’s disease

İbrahim KÖKÇAM, Selma BAKAR DERTLİOĞLU

Aim: Endothelial damage and dysfunction are held responsible for the etiopathogenesis of Behçet’s disease (BD). In the
present study, we aimed to investigate the relationship of BD with nitric oxide (NO), asymmetrical dimethylarginine
(ADMA), symmetrical dimethylarginine (SDMA) and L-arginine levels, which are known to play a role in the
pathogenesis of vasculitis.
Materials and methods: Sixty patients enrolled in the study were allocated to groups as follows: active/inactive patient
groups; the patient group with active/inactive vessel involvement, and mucocutaneous patient group without vessel
involvement.
Results: NO, SDMA, ADMA levels of the active patients and SDMA and ADMA levels of the inactive patients were
found to be significantly higher than those of the healthy controls. SMDA and ADMA levels in the group with active
vessel involvement; NO, SDMA, ADMA, and L-arginine levels in the group with inactive vessel involvement; and, NO,
SDMA, and ADMA levels of the mucocutaneous group were significantly higher than those of the healthy controls.
However we detected no statistically significant difference among the patient groups.
Conclusion: These criteria cannot be utilized in evaluating the activity of the disease and in predicting vessel involvement.
Key words: Behçet’s disease, nitric oxide, asymmetrical dimethylarginine, symmetrical dimethylarginine, L-arginine

Behçet hastalarında nitrik oksit ve metabolitlerinin düzeylerinin araştırılması
Amaç: Behçet hastalığının (BH) etiyopatogenezinde endotel hasarı ve fonksiyon bozukluğu suçlanmaktadır. Bu
çalışmada vaskülit patogenezinde rolü olduğu bilinen nitrik oksit (NO), asimetrik dimetilarginin (ADMA), simetrik
dimetilarginin (SDMA) ve L-Arjinin düzeyleri ile BH aktivitesi arasındaki ilişkinin incelemesi amaçlandı.
Yöntem ve gereç: Çalışmaya alınan 60 olgu aktif/inaktif hasta; damar tutulumu açısından da aktif/inaktif ve damar
tutulumu olmayan mukokutanöz olarak gruplandırıldı. Nitrit ve nitrat ölçümleri spektrofotometrik; diğer parametreler
HPLC cihazında florimetrik olarak ölçüldü.
Bulgular: Aktif hastaların NO, SDMA, ADMA seviyeleri ile inaktif hastaların SDMA ve ADMA seviyeleri sağlıklı
kontrol grubuna göre yüksek bulunurken, incelenen parametreler yönünden aktif /inaktif hasta grupları arasında
anlamlı bir fark yoktu. Damar tutulumu aktif grubun SMDA ve ADMA seviyeleri; damar tutulumu inaktif grubun NO,
SDMA, ADMA, L-arjinin seviyeleri ile mukokütanöz grubun NO, SMDA, ADMA seviyeleri sağlıklı kontrol grubuna
göre anlamlı derecede yüksek bulundu. Ancak, hasta grupları arasında anlamlı bir fark saptanmadı.
Sonuç: Çalışmada incelenen parametrelerin, hasta gruplarında sağlıklı kontrol grubuna göre anlamlı düzeyde yüksek
olmasına rağmen, hasta grupları arasında anlamlı bir fark olmaması; hastalığın aktivitesini değerlendirmede ve damar
tutulumunu göstermede yararlı birer kriter olarak kullanılamayacağı kanaatine varıldı.
Anahtar sözcükler: Behçet hastalığı, nitrik oksit, asimetrik dimetilarginin, simetrik dimetilarginin, L-arjinin
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Introduction
Behçet’s disease (BD) is a multisystem
inflammatory disorder, currently classified as
vasculitis. Small-vessel vasculitis is the pathological
basis of the multiorgan involvement that results in
protean clinical features (1,2).
The exact etiopathogenesis of BD remains to be
elucidated. Like most of the vasculitic pathologies, the
endothelial damage and dysfunction are apparently
associated with the etiopathogenesis of BD. Due to
vasculitis and inflammatory response, impairment
of endothelial function occurs or is accompanied by
endothelial damage. In the active stage of the disease,
a high systemic inflammatory activity is observed in
the circulation or the vascular tissue (3-5).
Nitric oxide (NO), a molecule synthesized by
endothelial cells, plays a pivotal role as a regulator
during the onset of immunological and inflammatory
reactions (6,7). NO is known to have prominent effects
on cellular cytotoxicity and leukocyte migration (8).
Dimethylarginines, which exist as symmetric and
asymmetric molecules, are analogues of L-arginine
(6). Asymmetrical dimethylarginine (ADMA) is
an endogenous inhibitor of nitric oxide synthesize.
An increased plasma ADMA level has been
observed in vascular diseases and is considered to
be a vascular risk factor (9,10). ADMA inhibits the
production of NO in cultured endothelial cells and
isolated blood vessels (11). Although studies have
indicated an association between high ADMA levels
and endothelial dysfunction (9,12), its role in the
pathogenesis of BD is unclear. The increased level of
ADMA in BD patients is thought to be associated with
increased synthesis and/or decreased breakdown of
ADMA molecule.

Today, practical laboratory parameters that
indicate the activity of BD and particularly vessel
involvement do not exist. Because of the fact that
endothelial damage and dysfunction are held
responsible for the pathogenesis of BD; NO, SDMA,
ADMA and L-arginine levels in BD patients with
vascular involvement were primarily investigated in
the present study. In the current study, it was aimed
to determine the relationship between BD and serum
levels of NO and its metabolites, which have a critical
role in immune reactions, in active and inactive
periods of BD.
Materials and methods
The study was conducted in patients who were
being followed up in Fırat University Medical School,
Dermatological and Venereal Diseases Clinic and
age- and gender-matched healthy controls.
Sixty patients that were diagnosed with BD in
accordance with the criteria of the International
Study Group (ISG) for BD were enrolled in the
study (16). The control group consisted of 24 healthy
volunteers precisely matched for age and sex. For the
present study, the approval of the Ethics Committee
and informed consent forms from all patients and
controls were obtained.

It is suggested that oxidative stress can cause the
level of ADMA to augment, increasing methylation
of L-arginine and inhibiting the enzymes breaking
ADMA down (5,6). It has been shown that the
parameters indicative of oxidative stress increase in
BD (13). Therefore, oxidative stress can be blamed for
the increased ADMA levels in BD.

The patients were evaluated regarding the
presence of symptoms and findings related to BD. At
the time of the study, the patients who met at least 1
criterion of ISG for BD were considered to be in the
active stage of the disease. The patients who had been
free of lesions for the previous 30 days or more were
taken as having inactive BD. In addition, the patients
with at least one of deep vein thrombosis, superficial
migratory thrombophlebitis, or large vessel
involvement were considered as patients with active
vessel involvement; and those with previous history
were considered as patients with inactive vessel
involvement. The patients without active or inactive
vessel involvement constituted the mucocutaneous
group.

Symmetrical dimethylarginine, one of the 3 types
of methylated arginine, is an isomer of ADMA (14).
L-arginine is a precursor of NO synthesis. Changes
in L-arginine/NO synthesis pathway could lead to
endothelial dysfunction (15).

Blood collection was performed in the morning
hours (0800-1000) after overnight fasting and 30
min of supine rest. The samples were centrifuged at
3500 rpm for 10 min to obtain plasma and serum.
The obtained samples were kept at -80 °C until
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analysis. Nitrite and nitrate levels were measured
spectrophotometrically according to a modified
method of Cortas et al. (17). Levels of L-arginine,
SDMA, and ADMA were measured fluorometrically
by a HPLC apparatus (high performance liquid
chromatography) using EUREKA kit (Head Quarter:
Via E. Fermi 25 60033 Chiaravalle (AN) Italy) with
programmable fluorescence detector.
Statistical analysis
SPSS v.12.0 was used to evaluate the obtained
data. All values were given as mean ± standard
deviation. Mann-Whitney U test was used to
compare the data obtained from patient and control
groups. In addition, Kruskal-Wallis test was used for
triple comparison of the data obtained from active,
inactive, and control patients. Paired comparison
of the groups in statistically significant results was
performed using the Mann-Whitney U test. And a P
value of <0.05 was regarded as statistically significant.
The Chi-square test was used for evaluating the
difference of gender between patients and controls.
Results
Of the 60 patients enrolled in the study, 32 were
male and 28 female. The mean age of the patients
was 37.28 ± 9.4 years (n = 60) and that of the control
group was 35.70 ± 9.9 years (n = 24). Of the patients,
42 (70%) were active and 18 (30%) inactive. No

statistically significant difference in age and gender
was found between control and patient groups (P >
0.05). Vascular involvement was seen in 42 (67.7%)
of the patients with BD, 17 (28.4%) and 25 (39.3%) of
whom were active and inactive, respectively.
When the mean NO, SDMA, ADMA values of
the group with active patients were compared with
those of the control group, the results of the patient
group were found to be statistically significantly
higher than those of the control group. A statistically
significant difference was detected in SDMA and
ADMA parameters between inactive patients and the
controls (Table 1).
SDMA and ADMA levels of the patient group
with active vessel involvement; NO, SDMA,
ADMA, and L-arginine levels of the patient group
with inactive vessel involvement; and, NO, SDMA,
ADMA levels of the group with mucocutaneous
patients were observed to be statistically significantly
higher than those of the healthy controls. No
statistically significant differences were detected in
these parameters among the patient groups (P > 0.05)
(Table 2).
BD is a multisystemic disease. Therefore, when
the patients were evaluated in terms of organ
involvement, while the mean level of serum ADMA
in patients with ocular involvement was significantly
higher compared to non-ocular involvement (P =
0.02), there were no significant difference in the other

Table 1. NO, SDMA, ADMA, and L-arginine values of the control and patient groups.
Patient groups

P

Active patients
(n = 42)

Inactive patients
(n = 18)

Control
(n = 24)

Active /
Inactive

Active /
Control

Inactive /
Control

NO
(μmol/L)

570.77 ± 12.76

528.88 ± 22.10

482.86 ± 14.75

NS

0.001

NS

SDMA
(μmol/L)

7.81 ± 0.50

6.71 ± 0.52

4.00 ± 0.15

NS

0.001

0.001

ADMA
(μmol/L)

55.02 ± 2.62

48.36 ± 2.79

5.02 ± 0.16

NS

0.001

0.001

L-arginine
(μmol/L)

109.86 ± 13.90

86.69 ± 17.93

71.16 ± 1.71

NS

0.040

NS

NS: Not significant
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Table 2. Plasma NO, SDMA, ADMA, and L-arginine values of patients regarding vascular involvement.

Patient groups
Healthy controls

Plasma constituents

Vessel involvement
active

Vessel involvement
inactive

Mucocutaneous

NO (μmol/L)

535.32 ± 32.42

536.28 ± 17.75 a

576.49 ± 14.52 a

482.86 ± 14.7

SDMA (μmol/L)

7.58 ± 0. 60 a

7.12 ± 0.66 a

7.60 ± 0.61 a

4.00 ± 0.15

ADMA (μmol/L)

44.60 ± 4.71 a

56.73 ± 4.39 a

54.40 ± 2.50 a

5.02 ± 0.16

L-arginine (μmol/L)

81.77 ± 18.61

111.42 ± 24.31 a

106.73 ± 15.73

71.16 ± 1.71

a

P < 0.001 as compared with control (Mann-Whitney U test)

parameters. In the active patients in terms of oral
ulcers, the serum level of NO was significantly higher
compared to the inactive patients (P = 0.03), but there
were no significant differences in SDMA, ADMA, and
L-arginine levels between active and inactive patients.
There were no significant differences in serum levels

of SDMA, ADMA, NO, and L-arginine between the
patients with genital ulcers, erythema nodosumlike lesions, CNS involvement, gastrointestinal
involvement, positivity in the pathergy test, and joint
involvement and the patients without these findings
(Table 3).

Table 3. The relationship between organ involvements, systemic involvements, and serum levels of NO, SDMA, ADMA, and L-arginine.

Ophthalmic
involvement
Oral ulcer
Genital ulcer
Erythema nodosumlike lesions
Acneiform lesions
Pathergy test
Joint involvement
CNS involvement
GIS involvement

590

Positive

NO
(μmol/L)
563.4 ± 84.5

SDMA
(μmol/L)
7.64 ± 2.03

Negative

557.2 ± 88.8

Positive

ADMA (μmol/L)

L-arginine (μmol/L)

63.97 ± 18.89*

113.2 ± 92.0

7.45 ± 3.19

51.09 ± 14.59*

101.0 ± 85.9

583.2 ± 65.9**

7.92 ± 3.81

55.00 ± 15.49

117.3 ± 96.4

Negative

536.2 ± 98.6**

7.09 ± 2.13

51.29 ± 16.14

90.2 ± 75.3

Positive

590.7 ± 68.0

7.29 ± 2.61

46.77 ± 11.23

72.1 ± 34.3

Negative

550.9 ± 90.3

7.52 ± 3.15

54.43 ± 16.44

109.8 ± 92.8

Positive

537.7 ± 102.3

6.86 ± 2.13

48.15 ± 12.06

71.5 ± 20.9

Negative

560.0 ± 86.9

7.53 ± 3.11

53.47 ± 16.13

105.7 ± 89.3

Positive

581.7 ± 99.7

8.53 ± 3.09

53.93 ± 19.49

110.1 ± 99.9

Negative

548.8 ± 81.6

7.06 ± 2.95

52.66 ± 14.36

100.0 ± 81.2

Positive

497.3 ± 82.1

7.57 ± 4.28

49.62 ± 15.36

66.4 ± 0.6

Negative

560.3 ± 87.6

7.48 ± 3.04

53.14 ± 15.95

104.1 ± 87.4

Positive

568.8 ± 70.5

6.37. ± 2.04

52.03 ± 8.30

96.4 ± 71.1

Negative

557.2 ± 89.4

7.58 ± 3.10

53.11 ± 16.38

103.5 ± 87.9

Positive

632.7 ± 128.1

6.85 ± 1.37

45.00 ± 18.15

133.7 ± 122.8

Negative

555.6 ± 86.2

7.50 ± 3.08

53.30 ± 15.84

101.8 ± 85.9

Positive

582.9 ± 116.4

6.61 ± 0.65

33.60 ± 7.12

52.1 ± 1.6

Negative

557.3 ± 87.5

7.51 ± 3.08

53.69 ± 15.63

104.6 ± 87.1

P
*P = 0.02
**P = 0.03
P > 0.05
P > 0.05
P > 0.05
P > 0.05
P > 0.05
P > 0.05
P > 0.05
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Discussion
Nitric oxide contributes to antithrombotic
features of the vascular wall through its functions,
such as thrombocyte adhesion and aggregation,
the adhesion of monocytes and leucocytes to
endothelium, vascular smooth muscle proliferation,
and the accumulation of superoxide radicals on the
vessel wall (6,18).
Various studies have demonstrated that both
increased and decreased NO levels may lead to
increased damage (10,11,13). Increased productions
of NO have been reported in various inflammatory
diseases, such as rheumatoid arthritis, SLE, Sjörgen
syndrome, vasculitis, and osteoarthritis (19). In 3
studies from Turkey, conducted in patients with
BD, serum NO levels were found to be statistically
significantly higher than healthy controls (20-22)
whereas in a study in 21 BD patients, Örem et al (23)
reported NO levels to be statistically significantly
lower than those of healthy controls.
In the studies conducted by Evereklioğlu et
al. (24) and Yıldırım et al. (25), to investigate the
relationship between plasma NO levels and disease
activity in patients with BD, plasma NO levels in the
active patient group was found to be significantly
higher than those of the inactive patient group. They
have suggested that the increased plasma NO levels
in the active stage of the disease might be responsible
for the inflammatory process in BD and NO could
be used as an activity criterion during the followup of the disease, indicating the severity. However,
Durukan et al. (26) did not detect any statistically
significant relationship between the activity of uveitis
and serum NO levels in BD patients with uveitis and
concluded that NO could not be used as an activity
criterion in the follow-up of the disease.
In the present study, plasma NO levels were
significantly higher in the active BD patients than
the healthy controls, but there was no significant
difference between active and inactive; and,
inactive and control groups. In terms of vascular
involvement, a significant increase was observed in
the mucocutaneous and inactive patients compared
to the control group
Our findings indicate that NO is increased in
BD, which however cannot be a criterion for activity
and vascular involvement. Hence, our results show
consistency with those of Durukan et al. (26).

Şahin et al. (6) found that plasma ADMA level
in BD patients with vascular involvement was
significantly higher than that of the group of patients
with mucocutaneous involvement and that of the
healthy controls. In the present study, plasma ADMA
levels were found to be significantly higher in all
patient groups (active, inactive, and mucocutaneous)
than that of the control group, whereas no significant
difference was observed when the patient groups
were compared among themselves.
Given that BD is vasculitis, ADMA levels are
increased during inflammatory process and our
results are consistent with those of other studies.
Symmetrical dimethylarginine, one of the 3 types
of methylated arginine, is an isomer of ADMA.
Because of the fact that SDMA has no effect on
the activity of nitric oxide synthase, ADMA is
regarded as a major type of endogenously formed
methylarginines, which inhibit the activity of nitric
oxide synthase (6). Therefore, ADMA levels were
reported to be increased with SDMA levels in diseases
with vessel involvement (27,28).
In the present study, plasma SDMA levels in all
patient groups were found to be significantly higher
than those of the control group, whereas there was
no statistically significant difference among the
patient groups. Depending on the fact that SDMA
has no effect on the activity of nitric oxide synthase
(27), it verifies the view that this parameter exerts its
effect through different mechanisms from those that
ADMA does and they are probably independent of
NO in the pathophysiology of BD.
To the best of our knowledge, there is no report
on plasma levels of L-arginine, which is a precursor
of NO synthesis in BD. Kielstein et al. (29) reported
that L-arginine levels in end-stage renal failure
patients with atherosclerosis were significantly
higher than those of patients with no atherosclerosis.
In the present study, L-arginine plasma levels reach
statistical significance between active BD patients and
control patients, and in terms of vessel involvement
between inactive patients and control groups. This
situation is not fully associated with the pathology
of vessel, and makes us consider that it is associated
with the increased inflammation in the active stage
of the disease.
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BD is a chronic inflammatory systemic vasculitis,
involving multiple systems. There are contradictory
reports on ADMA level in some diseases with
inflammation. Yoshida et al. (30) investigated the
levels of ADMA and pigment epithelium derived
factor (PEDF) in aqueous humour in the eyes of
patients with infectious and non-infectious acute
uveitis and patients with cataract. In that study, they
determined that the levels of ADMA and PEDF were
significantly higher in patients with uveitis compared
to control group and that there was a positive
correlation between the levels of ADMA and PEDF
in both groups. They suggested that it was associated
with inflammation.
Similarly, Sugai et al. (31) investigated the levels of
ADMA in serum and aqueous humour of the eyes of
diabetic patients and its relationship with the severity
of retinopathy. In that study, they reported that the
levels of ADMA in both serum and aqueous humour
were significantly higher in the diabetic patients with
particularly severe retinopathy compared to nondiabetic patients and that the levels of ADMA of
serum and aqueous humour were not correlated in
both groups.
In contrast to the studies given above, Blomster
et al. (32) reported that there were no significant
increases in the levels of ADMA, SDMA, and
arginine compared to control in patients with
exfoliation syndrome, whereas that there was
a significant increase in the SDMA level and a
significant decrease in arginine, which are correlated
with serum homocysteine level, in patients with
exfoliative glaucoma. They concluded that SDMA
is an important marker for the development of
hyperhomocysteinemia in patients with exfoliative
glaucoma.
In the current study, we determined a significant
increase in the serum ADMA level in patients with eye
involvement. We think that both the inflammatory
feature of the disease and the uveitis may a play role
in that increase.
In our study, the mean serum NO level was found
significantly higher in patients with active oral ulcers
compared to inactive patients. There might be several
reasons for the significant increase in serum NO level
in patients with active oral ulcers. NO is formed from
L-arginine by nitric oxide synthase enzyme. This
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enzyme has 3 different isoforms, namely neuronal
(nNOS or NOS-1), inducible (iNOS or NOS-2), and
endothelial (eNOS-NOS-3). iNOS enzyme produces
NO, being induced by exposure to cellular cytokines
including macrophage, endothelial cells and
smooth muscle cell and bacterial products, such as
endotoxins and lipopolisaccarides. Activity of iNOS
is long lasting and causes the production of a lot of
NO, since its activation is not Ca2+ and calmodulin
dependent. If the enzyme is induced, production of
NO lasts for hours, even days (33,34).
The bacterial flora of the mouth may change
nitrate in the saliva into nitrite and then NO. On the
other hand, ingested nitrite in the saliva can turn into
NO in the acidic medium of the stomach. Bacterial
infections, particularly streptococcal infections, are
blamed for the oral ulcers observed in BD. As a result,
these bacteria, on the one hand, cause ulcerations,
and on the other hand, induce NO synthesis for a
long time (35). In this case, it is not surprising for
NO level to be higher in BD patients with oral ulcers
than those without oral ulcers.
Yıldırım et al. (25) reported that NO level in
active BD patients was significantly higher than those
in inactive BD patients and patients with recurrent
aphthous stomatitis and healthy controls and that
there was no significant difference between inactive
patients and patients with recurrent aphthous
stomatitis. In the current study, we found that NO
levels were significantly higher in patients with oral
aphthous compared to those without oral aphthous.
In addition, the presence of oral aphthous in 46.7%
of the patients appears to suggest that it may be a
reflection of the increase of NO in patients with BD.
In conclusion, the parameters in question were
significantly higher in the patient groups compared
to the healthy control group. However, it was
concluded that these parameters cannot be used as
effective criteria in evaluating the disease activity
and predicting the vessel involvement because there
was no statistically significant difference among the
patient groups.
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